The New Cholesterol Treatment Guidelines from the American College of Cardiology/American Heart Association, 2013: What Clinicians Need to Know

References

• . Stone NJ, Robinson J, Lichtenstein AH,. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013]. Circulation. doi:10.1161/01.cir.0000437738.63853.7a
   Google Scholar
• . Pearlman BL. The new cholesterol guidelines. Applying them in clinical practice. Postgrad Med. 2002;112(2):13–16
   PubMed Web of Science ®Google Scholar
• . Baigent C, Keech A, Kearney PM,; Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278
   PubMed Web of Science ®Google Scholar
• . National Cholesterol Education Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421
   PubMedGoogle Scholar
• . Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762–1765
   PubMed Web of Science ®Google Scholar
• . Kabagambe EK, Judd SE, Howard VJ,. Inflammation biomarkers and risk of all-cause mortality in the Reasons for Geographic and Racial Differences in Stroke cohort. Am J Epidemiol. 2011;174(3):284–292
   PubMedGoogle Scholar
• . Muntner P, Colantonio LD, Cushman M,. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311(14):1406–1415
   PubMed Web of Science ®Google Scholar
• . 2013 Prevention Guidelines Tools: CV Risk Calculator. American Heart Association website. http://my.americanheart.org/professional/StatementsGuidelines/PreventionGuidelines/Prevention-Guidelines_UCM_457698_SubHomePage.jsp. Accessed January 10, 2014
   Google Scholar
• . Taylor F, Huffman MD, Macedo AF,. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816
   PubMed Web of Science ®Google Scholar
• . , The AIM-HIGH InvestigatorsBoden WE, Probstfield JL, Anderson T,. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267
   PubMed Web of Science ®Google Scholar
• . , The ACCORD Study GroupGinsberg HN, Elam MB, Lovato LC,. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574
   PubMed Web of Science ®Google Scholar
• . Eckel RH, Jakicic JM, Ard JD,. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013]. J Am Coll Cardiol. doi:10.1016/j.jacc.2013.11.003
   Google Scholar
• . Miller M, Stone NJ, Ballantyne C,. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–2333
   PubMed Web of Science ®Google Scholar
• . Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012;110(6):823–825
   PubMed Web of Science ®Google Scholar
• . Rekhraj S, Hsia J. Evaluation and management of lipid disorders. Curr Opin Cardiol. 1999;14(4):298–302
   PubMedGoogle Scholar
• . Berglund L, Brunzell JD, Goldberg AC,. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969–2989
   PubMed Web of Science ®Google Scholar
• . Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Danielson E, Fonseca FAH,. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207
   PubMed Web of Science ®Google Scholar
• . Amarenco P, Bogousslavsky J, Callahan A 3rd,. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–559
   PubMed Web of Science ®Google Scholar
• . Pedersen TR, Faergeman O, Kastelein JJP,. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445
   PubMed Web of Science ®Google Scholar
• . FDA Public Health Advisory for Crestor (rosuvastatin). Food and Drug Administration website. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforheathcareprofessionals/publichealthadvisories/ucm051756.htm. Published March 2, 2005. Accessed April 24, 2014
   Google Scholar
• . Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–571
   PubMed Web of Science ®Google Scholar
• . Sattar N, Preiss D, Murray HM. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36( Suppl 1):S11–S66
   PubMed Web of Science ®Google Scholar
• . Mohaupt MG, Karas, RH, Babiychuk EB,. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009;181(1–2):E11–E18
   PubMed Web of Science ®Google Scholar
• . FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Food and Drug Administration website. http://www.fda.gov/drugs/drugsafety/ucm256581.htm. Published June 8, 2011. Updated December 15, 2011. Accessed February 1, 2014
   Google Scholar
• . Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40(4):188–194
   PubMed Web of Science ®Google Scholar
• . Joy TR, Monjed A, Zou GY,. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160(5):301–310
   PubMed Web of Science ®Google Scholar
• . Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49(23):2231–2237
   PubMed Web of Science ®Google Scholar
• . Kjekshus J, Apetrei E, Barrios V,. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261
   PubMed Web of Science ®Google Scholar
• . Tavazzi L, Maggioni AP,. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–1239
   PubMed Web of Science ®Google Scholar
• . Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785–794
   PubMed Web of Science ®Google Scholar
• . Fellström BC, Jardine AG, Schmieder RE,. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407
   PubMed Web of Science ®Google Scholar
• . Wanner C, Krane V, März W. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248
   PubMed Web of Science ®Google Scholar
• . Hou W, Lv J, Perkovic V, Yang L,. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34(24):1807–1817
   PubMed Web of Science ®Google Scholar
• . Strippoli GF, Navaneethan SD, Johnson DW,. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645–651
   PubMedGoogle Scholar
• . Brown BG, Zhao XQ, Chait A,. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583–1592
   PubMed Web of Science ®Google Scholar
• . Rossebo AB, Pedersen TR, Boman K,. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–1356
   PubMed Web of Science ®Google Scholar
• . Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351–364
   PubMed Web of Science ®Google Scholar
• . Frick MH, Elo O, Haapa K,. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–1245
   PubMed Web of Science ®Google Scholar
• . Rubins HB, Robins SJ, Collins D,. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–418
   PubMed Web of Science ®Google Scholar
• . Keech A, Simes RJ, Barter P,. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861
   PubMed Web of Science ®Google Scholar
• . Yokoyama M, Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J. 2003;146(4):613–620
   PubMedGoogle Scholar
• . Becker DJ, Gordon RY, Halbert SC,. Red yeast rice for dyslipidemia in statin-intolerant patients. Ann Intern Med. 2009;150(12):830–839
   PubMed Web of Science ®Google Scholar
• . Kavousi M, Leening MJG, Nanchen D,. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311(14):1416–1423
   PubMed Web of Science ®Google Scholar
• . Downs J, Good C. New cholesterol guidelines: has Godot finally arrived? Ann Intern Med. 2014;160(5):354–355
   PubMedGoogle Scholar
• . Martin SS, Blumenthal RS. Concepts and controversies: The 2013 American College of Cardiology/American Heart Association Risk Assessment and Cholesterol Treatment Guidelines. Ann Intern Med. 2014;311(14):356–358
   Google Scholar
• . La Rosa JC, Grundy SM, Waters DD,. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;353(14):1425–1435
   Google Scholar
• . Tucker ME. Endocrinology group rejects new AHA/ACC CVD guidelines. Medscape website. http://www.medscape.com/viewarticle/817810. Accessed May 5, 2014
   Google Scholar
• . Pencina MJ, Navar-Boggan AM, D'Agostino RB,. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422–1431
   PubMed Web of Science ®Google Scholar